Mometasone
- PDF / 170,093 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 109 Downloads / 189 Views
1
S
Epistaxis: case report In a study of 375 patients (patients included from studies RESOLVE and RESOLVE II), one patient [age and sex not stated] was described, who developed epistaxis following the placement of mometasone implant for chronic rhinosinusitis with nasal polyps. The patient had chronic rhinosinusitis with nasal polyps and had prior ethmoid sinus surgery including bilateral total ethmoidectomy. The patient had recurrent bilateral nasal polyps despite daily use of unspecified intranasal corticosteroid sprays with unspecified oral steroids. The patient was recommended for revision endoscopic sinus surgery. The patient underwent in-office bilateral placement in the ethmoid sinuses under unspecified local anaesthesia of 2 mometasone implants [mometasone furoate; Sinuva], which were designed to release 1350 µg of mometasone over 90 days along with mometasone nasal sprays [mometasone furoate; Nasonex] 200 µg once daily (50 µg twice in each nostril) through day 90. However, during the treatment, the patient developed mometasone implant related serious adverse event in the form of epistaxis [duration of treatment to reaction onset and outcome not stated]. Author comment: "Patients randomised to the treatment group underwent in-office bilateral placement in the ethmoid sinuses under local anesthesia of 2 [mometasone] implants (SINUVA)." "One (0.4%) patient experienced implant-related serious adverse event (epistaxis)." Stolovitzky JP, et al. In-office Placement of Mometasone Furoate Sinus Implants for Recurrent Nasal Polyps: A Pooled Analysis. American Journal of Rhinology and Allergy 33: 545-558, No. 5, Sep 2019. Available from: URL: http:// 803434000 doi.org/10.1177/1945892419850924 - USA
0114-9954/19/1779-0001/$14.95 Adis © 2019 Springer Nature Switzerland AG. All rights reserved
Reactions 16 Nov 2019 No. 1779
Data Loading...
